Boehringer Ingelheim and the University of Texas MD Anderson Cancer Center entered a multi-year partnership to conduct collaborative translational research for lung and GI cancers.
Lovelace’s support and the inclusion in a $20m NIH contract enable Exemplar to continue the development of a porcine animal model for Sickle Cell Disease research.
StemoniX opens a new facility in California to house its research team working on its high-throughput microOrgan technology platforms for drug discovery and preclinical development.
Lovelace Biomedical leads a collaboration with The Jackson Laboratory, Exemplar Genetics, Iontox, and the University of Pennsylvania as part of a $20m contract with the NIH.
Translational research faces new challenges – and opportunities – with the rapid growth in precision medicine and new drug modalities, as the industry looks to quickly bring new treatments to patients.
Drug development advisory firm Rosa & Co. enters research agreement with Chugai pharmaceutical to provide access to PhysioPD research services for translational biology.
When translational medicine researchers recognise the need for pharma industry cash but are wary of handing over drug development to for-profit organisations, how can public-private collaborations bridge the culture gap?
Preclinical CRO Harlan Laboratories has partnered with French CRO Fluofarma to strengthen the companies’ drug discovery and translational medicine services.
Icon has boosted its Phase I translational medicine services in Manchester, UK, in preparation for what it believes will be a boom in the drug development area.
Quintiles is collaborating with Guy’s and St Thomas’ NHS Foundation Trust and King’s College London to establish a 30 bed Phase I site which will help meet demand for early-stage research conducted in patients.
Icon has entered into a collaboration with the Central Manchester University Hospitals Foundation (CMFT) to establish a purpose built translational medicine facility in the UK.
Invitrogen has announced the opening of a new research facility to
be located in Scotland. The decision adds to the investment influx
within the region, which has seen 20 per cent of the UK's biotech
companies set up research...